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The adipokine omentin, also known as intelectin, is a secretory
protein, expressed in visceral adipose tissue and is highly
abundant in plasma. It is involved in the development of chronic
inﬂammatory diseases, but nothing is known about its impact
on the cardiovascular event risk. Here, plasma omentin was
measured in 295 patients undergoing coronary angiography for
the evaluation of established or suspected stable coronary artery
disease (CAD). Patients were separated according to the median
plasma omentin concentrations into a high and low omentin
group and cardiovascular events occurring during a period of
3.5 years have been recorded. We observed that patients within
the high omentin group had signiﬁcantly more cardiovascular
events than patients in the low omentin group. This was
true even if using different study endpoints. This article
describes data related to a research article titled “High Plasma
Omentin Predicts Cardiovascular Events Independently Fromvier Inc. This is an open access article under the CC BY license
/j.atherosclerosis.2015.10.100
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C.H. Saely et al. / Data in Brief 6 (2016) 158–161 159the Presence and Extent of Angiographically Determined
Atherosclerosis” (Saely et al., 2015) [1].
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Clinical Research
ore speciﬁc subject area Epidemiology, Biomarkers
ype of data Figure
ow data was acquired Prospective study
ata format Analyze data
xperimental factors Omentin in plasma sample was measured by ELISA
xperimental features Omentin concentration in 295 coronary patients has been deter-
mined and cardiovascular events have been recorded during3.5
years.ata source location Feldkirch, Austria
ata accessibility Data is with this articleD1. Value of the data– Up to date, no prospective data on the power of the adipokine omentin to predict cardiovascular
events are available.
– The data from our prospective cohort study for the ﬁrst time shows that elevated plasma omentin
signiﬁcantly predicts cardiovascular events.
– This data are important, because the limited existing literature on omentin had rather suggested
beneﬁts on cardiometabolic parameters in other populations.
– The adipokine omentin may serve as a potential new biomarker in coronary patients.
– The data may stimulate future research addressing omentin in different patient cohorts.
2. Data
The data presented here show the incidence of cardiovascular events and study endpoints (EP)
respectively in 295 coronary patients according to their plasma omentin concentration. Patients were
separated into a group with high (above the median, n¼147) and low (below the median, n¼148)
omentin. The event-free survival (Fig. 1) was signiﬁcantly higher in the low omentin group than in the
high omentin group if including all cardiovascular events (EP A, pLog-Rank¼0.037), if including all
cardiovascular events but excluding revascularization in arterial beds (EP B pLog-Rank¼0.012), or if
including only major cardiovascular events (EP C; pLog-Rank¼0.019).3. Experimental design, materials and methods
3.1. Patients
From a large cohort of 1751 Caucasian patients, who were referred to coronary angiography for the
evaluation of established or suspected stable coronary artery disease (CAD), 295 were randomly
Fig. 1. Incidence of study endpoints by high and low omentin concentration in coronary patients. The survival plot indicates
event-free survival according to low (4.0–13.44 ng/ml) and high plasma omentin concentration (13.45–108.3 ng/ml) in
angiographied patients during 3.5 years. Study endpoint (EP) A comprise all cardiovascular events, including coronary death,
fatal ischemic stroke, non-fatal myocardial infarction, non-fatal ischemic stroke, and need for coronary artery bypass grafting,
percutaneous coronary intervention, or revascularization in the carotid or peripheral arterial beds (A). EP B comprises all events
of EP A but without revascularization in the carotid or peripheral arterial beds (B). EP C comprises only major cardiovascular
events, including coronary death, fatal ischemic stroke, non-fatal myocardial infarction, and non-fatal ischemic stroke (C).
C.H. Saely et al. / Data in Brief 6 (2016) 158–161160drawn, except for CAD status (161 had signiﬁcant CAD and 134 did not have signiﬁcant CAD) and sex
(140 women and 155 men). Patients with acute coronary syndromes were not included. In these 295
patients, we measured plasma omentin. Subsequently, these 295 patients were separated according
to the median of measured omentin concentrations into a high omentin group (n¼147) and a low
omentin group (n¼148). The present study has been approved by the Ethics Committee of the
University of Innsbruck; written informed consent was given by all participants.4. Laboratory analyses
Venous blood samples were collected after an overnight fast of 12 h before angiography was
performed and laboratory measurements were performed from fresh plasma samples. Plasma
omentin levels were determined with a commercial omentin enzyme-linked immunosorbent assay
(ELISA) kit (catalog no. SK00010-01; Aviscera Bioscience, CA, USA) from the same batch of kits (lot no.
20110234), speciﬁc for omentin-1 with an inter-assay variation less than 10%. We assessed a mean
(þSD) omentin concentration of 17.4 (þ14.3) ng/ml and a median of 13.4 (interquartile range 7.9–
21.5) ng/ml. Thus the data range is comparable to omentin levels reported for healthy control subjects
ranging from 14 to 34 ng/ml [2,3] and is also in line with other studies [3–8].5. Prospective study
Mortality data were collected annually from a national survey (Statistik Austria, Vienna, Austria);
follow-up visits to our institution were planned after 3–4 years in order to assess endpoints among
survivors. The mean follow up time was 3.5 71.1 years after the baseline investigation. To assess non-
fatal endpoints we conducted standardized interviews; additionally, hospital records were reviewed.
The data refer to cardiovascular events comprising coronary death (fatal myocardial infarction,
sudden cardiac death, mortality from congestive heart failure due to CAD), fatal ischemic stroke, non-
fatal myocardial infarction non-fatal ischemic stroke, and need for coronary artery bypass grafting
(CABG), percutaneous coronary intervention (PCI), or revascularization in the carotid or peripheral
arterial beds. The combination of all these events has been referred to as our primary study endpoint
(EP A). Additional endpoints include the composite of coronary death (fatal myocardial infarction,
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fatal myocardial infarction, non-fatal ischemic stroke, and need for coronary artery bypass grafting
(CABG) or percutaneous coronary intervention (PCI) – i.e. the primary endpoint without revascular-
ization in the carotid or peripheral arterial beds (¼EP B); and the composite of coronary death (fatal
myocardial infarction, sudden cardiac death, mortality from congestive heart failure due to CAD), fatal
ischemic stroke, non-fatal myocardial infarction and non-fatal ischemic stroke – i.e. major cardio-
vascular events (¼EP C).
Coronary angioplasty and bypass surgery were considered as cardiovascular events unless they
were planned as a consequence of the baseline angiography and therefore were not “future” events. A
follow-up rate of 95% was achieved.6. Statistical analysis
Survival analysis was performed using Kaplan–Meier and Log-Rank tests respectively. Patients
who were lost during the follow-up (n¼15) were not included in the prospective analyses. Statistical
analyses were performed with the software package SPSS 22.0 for Macintosh, IBM SPSS; Chicago, IL.Acknowledgments
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